Stocks · News reference
Alamar Biosciences, Inc. (NASDAQ:ALMR), a leader in precision proteomics dedicated to advancing the early detection of disease, today announced the launch of the NULISAseq™ Immune 340 Panel, its broadest multiplexed
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
3 health care stocks with high momentum could be overbought. Crinetics Pharmaceuticals (CRNX) has RSI of 90.6, Alamar Biosciences (ALMR) at 86.8, and Halozyme Therapeutics (HALO) at 81.7.
Read original at benzingaStifel analyst Daniel Arias maintains Alamar Biosciences (NASDAQ:ALMR) with a Buy and raises the price target from $28 to $32.
Read original at benzingaAlamar Biosciences expands its Alzheimer’s data partnership, adds 86,000 samples and reports Q2 sales growth of 82% year-over-year.
Read original at benzingaGainers Neuronetics (NASDAQ:STIM) shares moved upwards by 34.1% to $2.91 during Tuesday's regular session. The market value of their outstanding shares is at $151.0 million. As per the press release, Q2 earnings
Read original at benzinga